Zobrazeno 1 - 10
of 23
pro vyhledávání: '"John, Ieni"'
Autor:
Ramakrishna Nirogi, John Ieni, Vinod Kumar Goyal, Jyothsna Ravula, Satish Jetta, Anil Shinde, Pradeep Jayarajan, Vijay Benade, Veera Raghava Chowdary Palacharla, Dhanunjay Kumar Dogiparti, Venkat Jasti, Alireza Atri, Jeffrey Cummings
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 8, Iss 1, Pp n/a-n/a (2022)
Abstract Introduction This study explored the efficacy and safety of a serotonin‐6 receptor antagonist, masupirdine, as adjunct treatment in patients with moderate Alzheimer's disease (AD) concomitantly treated with donepezil and memantine. Methods
Externí odkaz:
https://doaj.org/article/2946c8a2c70042bc98555d45982352fa
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 317:1307-1319
Donepezil is a potent acetylcholinesterase inhibitor that also interacts with the sigma1 receptor, an intracellular neuromodulatory protein. In the present study, we analyzed the antiamnesic and neuroprotective activities of donepezil in a mouse hypo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c5efdf4bb1ac3797f6ed79607d6e9a6
https://doi.org/10.1124/jpet.106.101527
https://doi.org/10.1124/jpet.106.101527
Autor:
Richard H. Weisler, Sharon L. Rogers, P. Murali Doraiswamy, Xin Yu, H. Cecil Charles, Jacobo Mintzer, Carlos Perdomo, K. Ranga Rama Krishnan, John Ieni
Publikováno v:
American Journal of Psychiatry. 160:2003-2011
The authors examined the effect of the acetylcholinesterase inhibitor donepezil on magnetic resonance markers of neurodegeneration in Alzheimer's disease.In this randomized, double-blind, placebo-controlled pilot study, 67 patients with mild to moder
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08bdb987b7bf7db791e5a882d6dff5f6
https://doi.org/10.1176/appi.ajp.160.11.2003
https://doi.org/10.1176/appi.ajp.160.11.2003
Autor:
Raymond D. Pratt, Larry E. Tune, John R. Votaw, Carlos Perdomo, R.D. Jewart, Paul J. Tiseo, John M. Hoffman, John Ieni
Publikováno v:
The American Journal of Geriatric Psychiatry. 11:169-177
OBJECTIVE The authors evaluated the effects of donepezil (10 mg/day) versus placebo on brain glucose metabolism. METHODS This was a randomized, double-blind, parallel-group, 24-week pilot study in 28 patients with mild-to-moderate Alzheimer disease (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8902bf9c7d9c542c106d19e16e2bf470
https://doi.org/10.1097/00019442-200303000-00007
https://doi.org/10.1097/00019442-200303000-00007
Autor:
Rachelle S. Doody, R.D. Pratt, Carlos Perdomo, Richard C. Mohs, John C. Morris, Sharon L. Rogers, John Ieni
Publikováno v:
Neurology. 57:481-488
Objective: To examine the effects of donepezil compared with placebo on the preservation of function in patients with AD over a 1-year period.Methods: This was a prospective, 54-week, double-blind, placebo-controlled, survival to endpoint study. Pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::407a45596b146702e0eae19af6736298
https://doi.org/10.1212/wnl.57.3.481
https://doi.org/10.1212/wnl.57.3.481
Publikováno v:
Journal of the American Geriatrics Society. 53:1831-1833
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::761ea50e4ac8aa1d04df15a5ae70e23c
https://doi.org/10.1111/j.1532-5415.2005.53528_1_2.x
https://doi.org/10.1111/j.1532-5415.2005.53528_1_2.x
Publikováno v:
Drugsaging. 25(2)
Background: Donepezil is licensed for the treatment of mild-to-moderate Alzheimer’s disease (AD) at doses of 5–10 mg/day and has recently been approved in the US for severe AD. Multiple studies have suggested that donepezil 10 mg/day provides add
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74d6fd7cf340daa7b5c53c34770845c8
https://pubmed.ncbi.nlm.nih.gov/18257603
https://pubmed.ncbi.nlm.nih.gov/18257603
Publikováno v:
British journal of pharmacology. 149(8)
The acetylcholinesterase inhibitor, donepezil, is also a high affinity sigma(1) receptor agonist. We examined the involvement of sigma(1) receptors in its anti-amnesic and neuroprotective properties against amyloid beta(25-35) peptide-induced toxicit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a17d6d26da53f5abd130f1def7f3281
https://pubmed.ncbi.nlm.nih.gov/17057756
https://pubmed.ncbi.nlm.nih.gov/17057756
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 317(2)
In the present study, we examined the interaction of (+/-)-2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]-methyl]-1H-inden-1-one hydrochloride (donepezil), a potent cholinesterase inhibitor, with two additional therapeutically relevant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0680738270023034f1500bc3af0c651e
https://pubmed.ncbi.nlm.nih.gov/16397090
https://pubmed.ncbi.nlm.nih.gov/16397090
Autor:
Elias Schwam, Jane Hecker, Serge Gauthier, Howard Feldman, John Ieni, Yikang Xu, Bruno Vellas
Publikováno v:
International journal of geriatric psychiatry. 20(6)
Background There have been very limited investigations of cholinesterase inhibitor therapy in more advanced stages of Alzheimer's disease (AD). The efficacy and safety of donepezil were evaluated in post hoc analyses of a subgroup of patients with mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e73c505bc314ba8b782d7dec042a2a0
https://pubmed.ncbi.nlm.nih.gov/15920715
https://pubmed.ncbi.nlm.nih.gov/15920715